《新型冠狀病毒肺炎診療方案（試行第九版）》于3月15日公布。

People with mild COVID-19 infections will be placed in centralized isolation, rather than in designated hospitals, according to the latest version of the national diagnosis and treatment guideline released by the National Health Commission on Tuesday evening. The change is in response to the majority of cases involving the dominant Omicron strain being asymptomatic or only showing mild symptoms. As most do not need much treatment, admitting those with mild cases to designated hospitals will take up medical resources unnecessarily, the commission said in a statement explaining the new guideline.

國家衛(wèi)健委發(fā)布的最新版診療方案稱，輕型病例先實行集中隔離管理。這是根據(jù)各地反映的“奧密克戎變異毒株患者以無癥狀感染者和輕型病例為主，大多不需要過多治療，全部收治到定點醫(yī)院會占用大量醫(yī)療資源”等意見做出的調整。

To prevent cross infection, the guideline stressed that centralized quarantine facilities for mild cases should not take in overseas travelers and close contacts at the same time.

輕型病例相關集中隔離場所不能同時隔離入境人員、密切接觸者等人群。

"Those with mild infections will be given therapies and monitored during isolation," it said. "If their condition worsens, they will be transferred to designated hospitals for further treatment."

輕型病例隔離管理期間應做好對癥治療和病情監(jiān)測，如病情加重，應轉至定點醫(yī)院治療。

Another change is a shortening of the isolation period for recovered patients.

新版診療方案還調整了康復患者的隔離時間。

Instead of 14 days in isolation, after being discharged from hospital, patients only need monitor their health condition at home for seven days.

將“出院后繼續(xù)進行14天隔離管理和健康狀況監(jiān)測”修改為“解除隔離管理或出院后繼續(xù)進行7天居家健康監(jiān)測”。

In addition, two COVID-19 drugs approved recently by the national drug regulator have been added to the new guideline.They are Paxlovid, an antiviral medication developed by United States-based Pfizer, and a monoclonal antibody developed domestically.

另外，將國家藥監(jiān)局批準的兩種特異性抗新冠病毒藥物寫入診療方案，即：美國輝瑞公司開發(fā)的抗病毒藥——PF-07321332/利托那韋片（Paxlovid）和國產單克隆抗體（安巴韋單抗/羅米司韋單抗注射液）。

【相關詞匯】

集中隔離 centralized isolation

醫(yī)療資源 medical resources

奧密克戎 Omicron

參考來源：中國日報、中國網

編輯：Kirsten